These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19879807)

  • 21. Highly conserved sequences for human neutralization epitope on hemagglutinin of influenza A viruses H3N2, H1N1 and H5N1: Implication for human monoclonal antibody recognition.
    Yamashita A; Kawashita N; Kubota-Koketsu R; Inoue Y; Watanabe Y; Ibrahim MS; Ideno S; Yunoki M; Okuno Y; Takagi T; Yasunaga T; Ikuta K
    Biochem Biophys Res Commun; 2010 Mar; 393(4):614-8. PubMed ID: 20152806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
    Crowe BA; Brühl P; Gerencer M; Schwendinger MG; Pilz A; Kistner O; Koelling-Schlebusch K; Aichinger G; Singer J; Zeitlinger M; Müller M; Ehrlich H; Barrett PN
    Vaccine; 2010 Dec; 29(2):166-73. PubMed ID: 21055500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses?
    Gillim-Ross L; Subbarao K
    PLoS Med; 2007 Feb; 4(2):e91. PubMed ID: 17298170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Universal influenza vaccines, science fiction or soon reality?
    de Vries RD; Altenburg AF; Rimmelzwaan GF
    Expert Rev Vaccines; 2015; 14(10):1299-301. PubMed ID: 26104835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Seasonal, avian, and novel H1N1 influenza: prevention and treatment modalities.
    Sym D; Patel PN; El-Chaar GM
    Ann Pharmacother; 2009 Dec; 43(12):2001-11. PubMed ID: 19920156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
    Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
    Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
    J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization.
    Gao W; Soloff AC; Lu X; Montecalvo A; Nguyen DC; Matsuoka Y; Robbins PD; Swayne DE; Donis RO; Katz JM; Barratt-Boyes SM; Gambotto A
    J Virol; 2006 Feb; 80(4):1959-64. PubMed ID: 16439551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.
    Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ
    J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.
    Lu X; Liu F; Zeng H; Sheu T; Achenbach JE; Veguilla V; Gubareva LV; Garten R; Smith C; Yang H; Stevens J; Xu X; Katz JM; Tumpey TM
    Virology; 2014 Apr; 454-455():169-75. PubMed ID: 24725943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination.
    van Maurik A; Sabarth N; Dacho HS; Brühl P; Schwendinger M; Crowe BA; Noel Barrett P; Kistner O; Keith Howard M
    Vaccine; 2010 Feb; 28(7):1778-85. PubMed ID: 20018265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influenza vaccine 2008-2009.
    Med Lett Drugs Ther; 2008 Oct; 50(1296):77-9. PubMed ID: 18833032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice.
    Xie H; Liu TM; Lu X; Wu Z; Belser JA; Katz JM; Tumpey TM; Ye Z
    J Infect Dis; 2009 Dec; 200(12):1874-83. PubMed ID: 19909080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A survey of levels of antibodies against influenza viruses in the population of Wuxi City].
    You FX; Sun N; Ma GY; Wang MM; Sa D; Shi C; Wu JL; Lin X; Xiao Y; Qian YH; Jiang Y; Xie J; Ji YY; Guan HX
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct; 25(5):351-4. PubMed ID: 22338222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti N1 cross-protecting antibodies against H5N1 detected in H1N1 infected people.
    Frobert E; Bouscambert-Duchamp M; Escuret V; Mundweiler S; Barthélémy M; Morfin F; Valette M; Gerdil C; Lina B; Ferraris O
    Curr Microbiol; 2010 Jul; 61(1):25-8. PubMed ID: 20033691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seasoned adaptive antibody immunity for highly pathogenic pandemic influenza in humans.
    Lynch GW; Selleck P; Church WB; Sullivan JS
    Immunol Cell Biol; 2012 Feb; 90(2):149-58. PubMed ID: 21647170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses.
    Baras B; Bouveret N; Devaster JM; Fries L; Gillard P; Sänger R; Hanon E
    Influenza Other Respir Viruses; 2008 Nov; 2(6):251-60. PubMed ID: 19453402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influenza vaccination of children.
    Heikkinen T; Peltola V
    Lancet Infect Dis; 2009 Dec; 9(12):720-1. PubMed ID: 19879806
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.